CAC 40
8 088,24 +71,59 (+0,89 %) Euro Stoxx 50
5 006,85 +67,84 (+1,37 %) Dow Jones
38 239,66 +153,86 (+0,40 %) EUR/USD
1,0699 -0,0034 (-0,32 %) Gold future
2 349,60 +7,10 (+0,30 %) Bitcoin EUR
59 076,88 -809,82 (-1,35 %)
Ipsen S.A. (IPN.PA)
Ipsen S.A.
65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com
Secteur(s): Healthcare
Secteur d’activité: Drug Manufacturers - Specialty & Generic
Employés à temps plein: 5 325
Dirigeants clés
| Nom | Titre | Payer | Exercé | Année de naissance |
|---|---|---|---|---|
| Mr. David Loew | MD, CEO & Director | 2,11M | S.O. | 1967 |
| Mr. Aymeric Le Chatelier | Executive VP & CFO | 731,25k | S.O. | 1969 |
| Dr. Aidan Murphy Ph.D. | Executive VP and Head of Technical Operations | S.O. | S.O. | 1966 |
| Mr. Craig Marks | Vice-President of Investor Relations | S.O. | S.O. | S.O. |
| Mr. Francois Garnier | Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer | S.O. | S.O. | 1962 |
| Ms. Gwenan White | Executive VP and Head of Communications, Public Affairs & Sustainability | S.O. | S.O. | S.O. |
| Mr. Regis Mulot | Executive VP & Chief Human Resources Officer | S.O. | S.O. | 1966 |
| Ms. Dominique Bery | Head of Nordics & Baltics | S.O. | S.O. | 1971 |
| Mr. Bartosz Bednarz D.D.S. | Executive VP and Head of Global Product & Portfolio Strategy | S.O. | S.O. | S.O. |
| Mr. Philippe Lopes-Fernandes CBO | Executive VP & Chief Business Officer | S.O. | S.O. | S.O. |
Description
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Gouvernance d’entreprise
L’ISS Governance QualityScore de Ipsen S.A. en date du 1 avril 2024 est 7. Les scores principaux sont Audit : 8; Société : 7; Droits des actionnaires : 7; Compensation : 6.
